11-dehydro thromboxane B2 (11dhTxB2) levels affirmed as independent predictor of heart attack and stroke risk in aspirin-treated patients
DENVER, Nov. 5 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test November 9 - 11 in booth No. 2536 at the American Heart Association Scientific Sessions 2008 in New Orleans, La.
New CHARISMA trial findings recently published in the American Heart Association's peer-reviewed medical journal Circulation confirm that elevated urinary levels of the biomarker 11-dehydro thromboxane B2 (11dhTxB2) indicate an increased risk of heart attack, stroke and cardiac death.
The AspirinWorks Test by Corgenix is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.
"The American Heart Association conference is an ideal forum in which to discuss the findings on the relationship between elevated 11dhTxB2 levels and cardiovascular risk from the powerful and respected CHARISMA trial," said Gordon Ens, clinical director of Corgenix Medical Corporation. "This well-designed, prospective outcome study demonstrates the potential value of the AspirinWorks Test for optimizing an individual's aspirin therapy."
CHARISMA is a multinational, multicenter, randomized, parallel group, double-blind trial involving 15,603 patients with either clinically established cardiovascular disease or multiple risk factors. The CHARISMA sub-study involved a total of 3,261 aspirin-treated patients from 224 sites in 12 countries.
The AspirinWorks Test was launched in the U.S. in June 2007 following
FDA 510(k) clearance, and it is now available nationwide through major
medical laboratories as well as direct to consumers th
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved